

Judith C Maro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2346707/publications.pdf>

Version: 2024-02-01

41
papers

639
citations

758635

12
h-index

642321

23
g-index

42
all docs

42
docs citations

42
times ranked

777
citing authors

#	ARTICLE	IF	CITATIONS
1	Design of a National Distributed Health Data Network. <i>Annals of Internal Medicine</i> , 2009, 151, 341.	2.0	148
2	Development and validation of an automated HIV prediction algorithm to identify candidates for pre-exposure prophylaxis: a modelling study. <i>Lancet HIV</i> , 2019, 6, e696-e704.	2.1	87
3	Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. <i>Diabetes Care</i> , 2020, 43, 90-97.	4.3	36
4	Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic. <i>Epidemiology</i> , 2018, 29, 895-903.	1.2	34
5	Assessment of Quadrivalent Human Papillomavirus Vaccine Safety Using the Self-Controlled Tree-Temporal Scan Statistic Signal-Detection Method in the Sentinel System. <i>American Journal of Epidemiology</i> , 2018, 187, 1269-1276.	1.6	29
6	Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 481-492.	0.9	26
7	A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 827-837.	0.9	26
8	Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework. <i>Npj Digital Medicine</i> , 2021, 4, 170.	5.7	25
9	Using and improving distributed data networks to generate actionable evidence: the case of real-world outcomes in the Food and Drug Administration's Sentinel system. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 793-797.	2.2	24
10	Development and Application of Two Semi-Automated Tools for Targeted Medical Product Surveillance in a Distributed Data Network. <i>Current Epidemiology Reports</i> , 2017, 4, 298-306.	1.1	16
11	Using the Self-Controlled Tree-Temporal Scan Statistic to Assess the Safety of Live Attenuated Herpes Zoster Vaccine. <i>American Journal of Epidemiology</i> , 2019, 188, 1383-1388.	1.6	15
12	Using electronic health records to identify candidates for human immunodeficiency virus pre-exposure prophylaxis: An application of super learning to risk prediction when the outcome is rare. <i>Statistics in Medicine</i> , 2020, 39, 3059-3073.	0.8	15
13	Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 839-848.	0.9	14
14	Validity of ICD-10-CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 899-909.	0.9	11
15	Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives. <i>JAMA Internal Medicine</i> , 2018, 178, 1482.	2.6	10
16	A Broad Safety Assessment of the 9-Valent Human Papillomavirus Vaccine. <i>American Journal of Epidemiology</i> , 2021, 190, 1253-1259.	1.6	10
17	Responding to Vaccine Safety Signals during Pandemic Influenza: A Modeling Study. <i>PLoS ONE</i> , 2014, 9, e115553.	1.1	9
18	Medical Product Safety Surveillance. <i>Epidemiology</i> , 2013, 24, 692-699.	1.2	8

#	ARTICLE	IF	CITATIONS
19	A Synthesis of Current Surveillance Planning Methods for the Sequential Monitoring of Drug and Vaccine Adverse Effects Using Electronic Health Care Data. EGEMS (Washington, DC), 2017, 4, 17.	2.0	8
20	Leveraging the Capabilities of the FDA's Sentinel System To Improve Kidney Care. Journal of the American Society of Nephrology: JASN, 2020, 31, 2506-2516.	3.0	8
21	A General Propensity Score for Signal Identification Using Tree-Based Scan Statistics. American Journal of Epidemiology, 2021, 190, 1424-1433.	1.6	8
22	Health outcomes coding trends in the US Food and Drug Administration's Sentinel System during transition to International Classification of Diseases-10 coding system: A brief review. Pharmacoepidemiology and Drug Safety, 2021, 30, 838-842.	0.9	8
23	A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine. American Journal of Epidemiology, 2022, 191, 957-964.	1.6	7
24	Consequences of Depletion of Susceptibles for Hazard Ratio Estimators Based on Propensity Scores. Epidemiology, 2020, 31, 806-814.	1.2	6
25	Impact of exposure accrual on sequential postmarket evaluations: a simulation study. Pharmacoepidemiology and Drug Safety, 2011, 20, 1184-1191.	0.9	5
26	The Devil's in the details: Reports on reproducibility in pharmacoepidemiologic studies. Pharmacoepidemiology and Drug Safety, 2019, 28, 671-679.	0.9	5
27	Use of FDA's Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure. Drug Safety, 2019, 42, 897-906.	1.4	5
28	Validation of an electronic algorithm for Hodgkin and non-Hodgkin lymphoma in ICD-10-CM. Pharmacoepidemiology and Drug Safety, 2021, 30, 910-917.	0.9	5
29	Exact sequential test for clinical trials and post-market drug and vaccine safety surveillance with Poisson and binary data. Statistics in Medicine, 2021, 40, 4890-4913.	0.8	5
30	Statistical Power for Postlicensure Medical Product Safety Data Mining. EGEMS (Washington, DC), 2017, 5, 6.	2.0	5
31	Orphan Therapies: Making Best Use of Postmarket Data. Journal of General Internal Medicine, 2014, 29, 745-751.	1.3	4
32	Automated Identification of Potential Candidates for Human Immunodeficiency Virus Pre-exposure Prophylaxis Using Electronic Health Record Data. Open Forum Infectious Diseases, 2016, 3, .	0.4	3
33	Leveraging the entire cohort in drug safety monitoring: part 1 methods for sequential surveillance that use regression adjustment or weighting to control confounding in a multisite, rare event, distributed data setting. Journal of Clinical Epidemiology, 2019, 112, 77-86.	2.4	3
34	Evaluation of Use of Technologies to Facilitate Medical Chart Review. Drug Safety, 2019, 42, 1071-1080.	1.4	3
35	Reproducing Protocol-Based Studies Using Parameterizable Tools—Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks. Clinical Pharmacology and Therapeutics, 2020, 107, 966-977.	2.3	3
36	Quantifying how small variations in design elements affect risk in an incident cohort study in claims. Pharmacoepidemiology and Drug Safety, 2020, 29, 84-93.	0.9	3

#	ARTICLE	IF	CITATIONS
37	Utility of fertility procedures and prenatal tests to estimate gestational age for liveâ€births and stillbirths in electronic health plan databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .	0.9	1
38	Go BIG and Go Global: Executing Large-Scale, Multi-Site Pharmacoepidemiologic Studies Using Real-world Data. <i>American Journal of Epidemiology</i> , 0, , .	1.6	1
39	Yih et al. Respond to â€œMoving From Evidence to Impact for Human Papillomavirus Vaccinationâ€: <i>American Journal of Epidemiology</i> , 2018, 187, 1281-1281.	1.6	0
40	Conducting prospective sequential surveillance in realâ€world dynamic distributed databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1331-1335.	0.9	0
41	Concomitant Filled Prescriptions of Oxymorphone or Oxycodone with CYP3A Inhibitors and Inducers. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 668-672.	0.5	0